FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562841606> ?p ?o ?g. }

• W2562841606 abstract "Abstract Background: For elderly patients unfit for intensive chemotherapy in acute myeloid leukemia (AML), low-dose cytarabine (LDAC; 20 mg SQ BID for 10 days) still remains to be the standard treatment, despite its unsatisfactory complete response (CR) rate of 18% and median overall survival (OS) of < 6 months (Burnett, 2007). Recently, there have been huge efforts to develop more effective and less-toxic therapies, such as decitabine, azacitidine, clofarabine, or gemtuzumab ozogamicin, but their benefits were not concrete, even though they were compared to the classical LDAC. To improve outcomes of the classical LDAC, we modified it by giving a higher dose of cytarabine for an extended duration in combination with oral etoposide. Herein, we present the results. Methods: Between 2002 and 2014, 93 consecutive older (≥ 60 years) patients with AML, who were unfit for intensive chemotherapy, received 1st cycle of modified LDAC (mLDAC) regimen consisting of cytarabine (20 mg/m2 SQ BID) and oral etoposide (50 mg PO BID) for 14 days. Thereafter, they received additional subsequent cycles (for a maximum of 7 cycles) for 10 days every 6 to 8 weeks. We retrospectively analyzed their overall response (OR), disease-free survival (DFS), and overall survival (OS) rates. In this analysis, OR was defined as CR plus CR with incomplete platelet recovery (CRp) or blood count recovery (CRi). Results: The median age of patients in our cohort, including 69 (74.2%) with poor performance status (ECOG ≥ 2), 15 (16.1%) with AML with myelodysplastic-related changes or secondary AML, and 13 (14.0%) with poor cytogenetic risk, was 68 years (range, 60-83). The median number of mLDAC regimen cycles which they received was 2 (range, 1-8). Clinically relevant toxicities of grade III-IV including nausea/vomiting, diarrhea, hyperbilirubinemia and neutropenic fever were observed in 4 (4.3%) patients, 6 (6.5%), 3 (3.2%), and 42 (45.2%), respectively, which were comparable with those of classical LDAC (Burnett, 2007). The early mortality rates at 30 and 60 days were 11.8% and 15.0%, respectively. The OR was observed in 45 (48.4%) patients, including 34 (36.6%) CR, 7 (7.5%) CRp, and 4 (4.3%) CRi, within two cycles of mLDAC. With median follow-up duration of 26.1 months, the median DFS and OS were 6.2 and 15.8 months, respectively. For patients who achieved OR, they were 14.5 and 36.9 months, respectively. The OR of patients who had poor cytogenetic risk was not significantly different compared to others (57.1%, 46.2%, and 38.5% for favorable, intermediate, and poor cytogenetics, respectively; P=0.50). However, they showed significantly shorter median DFS (9.8, 6.6, and 5.1 months, respectively; P=0.01) and OS (NR, 1.4, and 5.1 months, respectively; P=0.01) with significantly shorter OR duration (30.6, 19.1, and 8.6 months, respectively; P=0.01). Between 2009 and 2014, among 17 patients treated with hypomethylating agents (HMA; 14 decitabine and 3 azacitidine), 1 CR and 3 partial response were achieved with a median survival of 5.5 months, and 5 patients after HMA treatment failure received subsequent mLDAC, and 3 achieved additional CR (n=2) and CRp (n=1). Conclusions: These results suggest that the outcomes of classical LDAC in elderly patients with AML can be improved by modifying it, with improved response and survival rates without increasing toxicities, even in patients with poor cytogenetics. Additionally, mLDAC could induce clinical responses in patients with HMA failure. Our mLDAC regimen may become another therapeutic option with emerging novel agents for elderly patients with AML, and these should be confirmed by large randomized trials. Disclosures No relevant conflicts of interest to declare." @default.
• W2562841606 created "2017-01-06" @default.
• W2562841606 creator A5014324967 @default.
• W2562841606 creator A5021692797 @default.
• W2562841606 creator A5026190297 @default.
• W2562841606 creator A5033356298 @default.
• W2562841606 creator A5034751203 @default.
• W2562841606 creator A5036020306 @default.
• W2562841606 creator A5044372572 @default.
• W2562841606 creator A5050292329 @default.
• W2562841606 creator A5055206475 @default.
• W2562841606 creator A5059291757 @default.
• W2562841606 creator A5061707434 @default.
• W2562841606 creator A5079417302 @default.
• W2562841606 creator A5084426605 @default.
• W2562841606 creator A5086415059 @default.
• W2562841606 creator A5086500437 @default.
• W2562841606 date "2015-12-03" @default.
• W2562841606 modified "2023-10-09" @default.
• W2562841606 title "Improved Outcomes of Low-Dose Cytarabine Regimen By Increased Dose and Duration of Cytarabine in Combination with Oral Etoposide for Elderly Acute Myeloid Leukemia" @default.
• W2562841606 doi "https://doi.org/10.1182/blood.v126.23.1338.1338" @default.
• W2562841606 hasPublicationYear "2015" @default.
• W2562841606 type Work @default.
• W2562841606 sameAs 2562841606 @default.
• W2562841606 citedByCount "0" @default.
• W2562841606 crossrefType "journal-article" @default.
• W2562841606 hasAuthorship W2562841606A5014324967 @default.
• W2562841606 hasAuthorship W2562841606A5021692797 @default.
• W2562841606 hasAuthorship W2562841606A5026190297 @default.
• W2562841606 hasAuthorship W2562841606A5033356298 @default.
• W2562841606 hasAuthorship W2562841606A5034751203 @default.
• W2562841606 hasAuthorship W2562841606A5036020306 @default.
• W2562841606 hasAuthorship W2562841606A5044372572 @default.
• W2562841606 hasAuthorship W2562841606A5050292329 @default.
• W2562841606 hasAuthorship W2562841606A5055206475 @default.
• W2562841606 hasAuthorship W2562841606A5059291757 @default.
• W2562841606 hasAuthorship W2562841606A5061707434 @default.
• W2562841606 hasAuthorship W2562841606A5079417302 @default.
• W2562841606 hasAuthorship W2562841606A5084426605 @default.
• W2562841606 hasAuthorship W2562841606A5086415059 @default.
• W2562841606 hasAuthorship W2562841606A5086500437 @default.
• W2562841606 hasConcept C126322002 @default.
• W2562841606 hasConcept C141071460 @default.
• W2562841606 hasConcept C2776694085 @default.
• W2562841606 hasConcept C2778041864 @default.
• W2562841606 hasConcept C2778119113 @default.
• W2562841606 hasConcept C2778336483 @default.
• W2562841606 hasConcept C2780580376 @default.
• W2562841606 hasConcept C2781413609 @default.
• W2562841606 hasConcept C71924100 @default.
• W2562841606 hasConcept C90924648 @default.
• W2562841606 hasConceptScore W2562841606C126322002 @default.
• W2562841606 hasConceptScore W2562841606C141071460 @default.
• W2562841606 hasConceptScore W2562841606C2776694085 @default.
• W2562841606 hasConceptScore W2562841606C2778041864 @default.
• W2562841606 hasConceptScore W2562841606C2778119113 @default.
• W2562841606 hasConceptScore W2562841606C2778336483 @default.
• W2562841606 hasConceptScore W2562841606C2780580376 @default.
• W2562841606 hasConceptScore W2562841606C2781413609 @default.
• W2562841606 hasConceptScore W2562841606C71924100 @default.
• W2562841606 hasConceptScore W2562841606C90924648 @default.
• W2562841606 hasLocation W25628416061 @default.
• W2562841606 hasOpenAccess W2562841606 @default.
• W2562841606 hasPrimaryLocation W25628416061 @default.
• W2562841606 hasRelatedWork W1585096943 @default.
• W2562841606 hasRelatedWork W1940304947 @default.
• W2562841606 hasRelatedWork W2191942260 @default.
• W2562841606 hasRelatedWork W2244303910 @default.
• W2562841606 hasRelatedWork W2249350519 @default.
• W2562841606 hasRelatedWork W2488091784 @default.
• W2562841606 hasRelatedWork W2509069476 @default.
• W2562841606 hasRelatedWork W2545351978 @default.
• W2562841606 hasRelatedWork W2551779547 @default.
• W2562841606 hasRelatedWork W2557237650 @default.
• W2562841606 hasRelatedWork W2558470513 @default.
• W2562841606 hasRelatedWork W2565834837 @default.
• W2562841606 hasRelatedWork W2566918577 @default.
• W2562841606 hasRelatedWork W2588283253 @default.
• W2562841606 hasRelatedWork W2591938638 @default.
• W2562841606 hasRelatedWork W2595261433 @default.
• W2562841606 hasRelatedWork W2886917823 @default.
• W2562841606 hasRelatedWork W3031253044 @default.
• W2562841606 hasRelatedWork W3131481795 @default.
• W2562841606 hasRelatedWork W378987734 @default.
• W2562841606 isParatext "false" @default.
• W2562841606 isRetracted "false" @default.
• W2562841606 magId "2562841606" @default.
• W2562841606 workType "article" @default.